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Recombinant antibody phage display technology is a vital tool that facilitates identiﬁcation of speciﬁc binding molecules to a
target enabling the rapid generation and selection of high aﬃnity, fully human, or mouse antibody product candidates essentially
directed towards disease target appropriate for antibody therapy. In this study, a recombinant single-chain Fv antibody fragment
(scFv) A11 was isolated from immune spleen cells obtained from mice immunized with inactivated rabies virus (Pasteur strain)
using standard methodology and was characterized for its speciﬁcity towards the rabies virus glycoprotein. Epitope mapping using
peptide libraries and truncated glycoprotein polypeptides suggested that A11 bound to the antigenic site II of rabies glycoprotein
against which a majority of rabies virus neutralizing antibodies are directed. The use of the above technology could, therefore,
allow development of scFvs with diﬀerent speciﬁcities against the rabies glycoprotein as an alternative to the more cumbersome
protocols used for the development of monoclonal antibodies.
1.Introduction
Rabies is a viral, zoonotic, and invariably fatal neuroinvasive
disease of humans caused by the bite of rabid animal. More
than 55,000 deaths occur annually worldwide in spite of the
use of postexposure therapy preventive measures, making
rabies one of the major causes of human mortality despite
signiﬁcant scientiﬁc progress [1, 2]. Administration of anti-
virus immunoglobulins includes the use of both human and
equine antirabies immunoglobulins along with vaccination
and is the only strategy recommended by WHO for the pos-
texposure prophylactic treatment of rabies [3]. Most of these
immunoglobulins are plasma-derived, polyclonal products
obtained from human and animal donors vaccinated against
rabies which can be produced in limited amounts and suﬀer
from potential drawbacks such as batch-to-batch variation
and the risk of contamination from other pathogens [4, 5].
Several conventional monoclonal antibodies (MAbs)
have been generated against diﬀerent viruses [6] and their
utilization tendstobelimitedinclinicalapplicationsbecause
of possible viral contamination and high cost involved in
MAb preparations. To overcome these problems, generation
of single chain antibody fragments (scFv) through phage
display technology has been utilized as the methodology of
choice [7–9]. Use of phage display technology as a powerful
in vitro tool for production of therapeutically important
antibodies against viral pathogens on the surface of bac-
teriophage provides an eﬃcient method for isolation and
screening of a diverse set of human and nonhuman anti-
bodies from immunized or na¨ ıve volunteers against various
infectious diseases. These antibodies have the potential of
being used as immunoprophylactic/therapeutics against dif-
ferent disease-causing agents [10–15].
In the present study, an immune scFv library was con-
structedusingRNAisolatedfromsplenocytesofmiceimmu-
nized with an inactivated rabies vaccine. Speciﬁc mouse scFv
fragment was aﬃnity selected from this library using inacti-
vatedrabiesvirus.TheselectedscFvA11wasshowntorecog-
nize an epitope on rabies glycoprotein (GP) antigenic site
II using immune phage display library, which was further2 Biotechnology Research International
conﬁrmed through its reactivity to truncated polypeptides of
PV GP containing the site.
2.MaterialandMethods
2.1. Antigens, Antibodies, and Animals. Inactivated Pasteur
virus rabies vaccine (AbhayRab) and puriﬁed rabies virus
were obtained from Human Biologicals Institute, Ooty,
India. Chikungunya antigen and its polyclonal antibodies,
hepatitis A antigen and its polyclonal antibodies were
procured from virology laboratory, Indian Immunologicals
limited (IIL). Hepatitis B surface antigen and its monoclonal
antibody (1F6) were obtained from hybridoma labora-
tory, IIL. Splenocytes were obtained from BALB/c mice
immunized with Abhayrab (Pasteur strain); puriﬁed native
glycoproteins from Pasteur virus (PV GP) were obtained
from the hybridoma Laboratory, IIL, for construction of
immune antibody phage display library.
2.2. Bacterial Strains, Vectors, and Chemicals. The bacterial
strains used for protein overexpression in E. coli BL21(DE3),
M13K07 helper phage for recombinant phage produc-
tion, and all molecular biology reagents were purchased
from invitrogen (Carlsbad, USA). The phagemid vector
pCANTAB 5E used for cloning and expression of the scFvs
on phage coat protein (pIII) was kindly provided by Dr.
Sandra Saptas (CSIRO, Australia). The bacterial expression
vector pET 20b was purchased from Novagen (Madison,
USA). The plasmid mini-prep kit for isolation of plasmid,
gel extraction kit for extraction of DNA, PCR puriﬁcation
kit, HiFi Taq DNA polymerase, PCR reagents, and Ni-NTA
agaroseused forthepuriﬁcation of His-tagged proteins were
purchased from Qiagen (Hilden, Germany). The bacterial
strain (E. coli TG1) used for the propagation of phagemid
vector pCANTAB 5E was purchased from Stratagene, USA.
Nuclease-freewaterandT4DNALigasewerepurchasedfrom
GeNei, India. Glutathione agarose used for puriﬁcation of
GST tagged proteins and all other ﬁne chemicals used were
purchased from Sigma (USA).
2.3. Isolation of Total RNA and cDNA Synthesis. Total RNA
was isolated from about 10 × 106 spleen cells collected
from immunized mice using TRIzol reagent (Invitrogen)
and resuspended in nuclease-free water. RNA was quantiﬁed
by Biophotometer (Eppendorf, USA) and was subjected to
cDNA synthesis using random hexamers and Thermoscript
reverse transcriptase (RT)-PCR kit (Invitrogen) according
to the manufacturer’s instructions. The cDNA was stored at
−20◦C until further use.
2.4. PCR Ampliﬁcation of Heavy and Light Chain Variable
Genes. PCR reaction was set up in a total volume of 50μL
containing 5μL of cDNA, 5μL of 10x HiFi Taq DNA
polymerase reaction buﬀer, 1μL of 10mM dNTP’s, 1μL
(10pmol/μL) of each forward and reverse universal, degene-
rate primer (synthesized by MWG, India) (Table 1)[ 16],
and 1.25 units of HiFi Taq DNA polymerase enzyme. After
chilling the reaction mix on ice, it was transferred to a master
cycler (Eppendorf) and cycled 7 times for 60sec at 92◦C,
30sec at 63◦C, 50sec at 58◦C, and 60sec at 68◦C followed
by 60sec at 92◦C, 60sec at 63◦C, and 60sec at 68◦Cf o r2 3
cycles. Finally the extension cycle was increased to 10min
at 68◦C. Ampliﬁcations were repeated several times, and the
ﬁnal variable light chain (VL) and variable heavy chain (VH)
products were pooled and gel puriﬁed.
2.5. Assembly of VH and VL and Cloning into Phagemid
Vector. Variable domains were ampliﬁed as described above,
gel puriﬁed, and assembled by a linker (Gly4Ser)3 using
splicing by overlap extension polymerase chain reaction
(SOE PCR) with VL forward and VH reverse primers
(Table 1). Puriﬁed VH and VL were used in PCR for 14
cycles in the absence of primers. The ampliﬁed PCR product
was reused as the template for amplifying (94◦Cf o r6 0s e c ,
63◦C for 60sec, 68◦C for 2min, 34 cycles) scFv which
yielded a product of size ∼750bp using forward light chain
primer (with NcoI site) and reverse heavy chain primer
(with NotI site) for 34 cycles. The PCR product containing
the ampliﬁed scFv was gel puriﬁed by gel extraction kit
and cloned into pCANTAB 5E vector, which was double,
digested with NcoIa n dNotI restriction enzymes according
to the manufacturer’s instructions (New England Biolabs,
MA,USA).Thedigestedproductswerefurtherpuriﬁedusing
a PCR puriﬁcation kit, and ∼98ng of the digested scFv
fragment was ligated into ∼100ng of digested phagemid
vector (pCANTAB 5E) in a total volume of 20μL using
T4 DNA ligase. The ligated product was electroporated
into electrocompetant E. coli TG1 cells (Stratagene, USA,
transformation eﬃciency of 1 × 109/μgo fD N A )u s i n ga n
electroporator (Gene pulser Xcell, Bio-Rad, USA), and the
transformed bacteria were plated on 2xYT agar.
2.6. Preparation of Phage Library. The resultant lawn of
bacterial cells that was obtained after transformation on
selective antibiotic media were scraped oﬀ the agar plates
into 15mL 2xYT media (2x Yeast extract, Tryptone) and
stored at −70◦C in aliquots of 1mL containing 20% glycerol.
An aliquot was thawed and diluted with 9mL of 2xYT
containing 50μg/mL of ampicillin and 2% glucose (2xYT-
AG). These bacterial cells were infected with 6 × 1010 plaque
formingunits(pfu)ofM13K07(Invitrogen)andtheinfected
bacteria were incubated in an orbital shaker at 37◦Cf o r
2h. The cells were collected by centrifugation at 5000rpm
for 10min and resuspended in 10mL of 2xYT containing
100μg/mL of ampicillin and 50μg/mL of kanamycin. The
culture were grown overnight at 37◦C before harvesting.
The supernatant-containing phages were ﬁltered through
a0 . 4 5 μm ﬁlter and concentrated by precipitation with
1/5th volume polyethylene glycol solution (20% PEG 6000,
2.5M NaCl) for 1h on ice. The precipitated phagemids
were centrifuged (20min, 6000×g, 4◦C) and resuspended
in phosphate-buﬀered saline (PBS). Following another brief
centrifugation at 4◦C for 5min at 13000×g, the cellular
debris was removed. The concentration of the infectious
phage particles was determined by infecting log phase E. coli
strainTG1cellswithseriallydilutedphagesranging from102Biotechnology Research International 3
Table 1: cmd Primers used for PCR of VH and VL regions and SOE PCR for construction of scFv.
Variable light chain forward primers
LB1 GCCATGGCGGA(CT)ATCCAGCTGACTCAGCC
LB2 GCCATGGCGGA(CT)ATTGTTCTC(AT)CCCAGTC
LB3 GCCATGGCGGA(CT)ATTGTG(AC)T(AC)ACTCAGTC
LB4 GCCATGGCGGA(CT)ATTGTG(CT)T(AG)ACACAGTC
LB5 GCCATGGCGGA(CT)ATTGT(AG)ATGAC(AC)CAGTC
LB6 GCCATGGCGGA(CT)ATT(AC)AGAT(AG)A(AC)CCAGTC
LB7 GCCATGGCGGA(CT)ATTCAGATGA(CT)(AGT)CAGTC
LB8 GCCATGGCGGA(CT)AT(CT)CAGATGACACAGAC
LB9 GCCATGGCGGA(CT)ATTGTTCTCA(AT)CCAGTC
LB10 GCCATGGCGGA(CT)ATTG(AT)GCT(GC)ACCCAATC
LB11 GCCATGGCGGA(CT)ATT(GC)T(AG)ATGACCCA(AG)TC
LB12 GCCATGGCGGA(CT)(AG)TT(GT)TGATGACCCA(AG)AC
LB13 GCCATGGCGGA(CT)ATTGTGATGAC(GCT)CAG(GT)C
LB14 GCCATGGCGGA(CT)ATTGTGATAAC(CT)CAGGA
LB15 GCCATGGCGGA(CT)ATTGTGATGACCCAG(AT)T
LB16 GCCATGGCGGA(CT)ATTGTGATGACACAACC
LB17 GCCATGGCGGA(CT)ATTTTGCTGACTCAGTC
Variable light chain reverse primers
LF1 GGAGCCGCCGCCGCCAGAACCACCACCACCAGAACCACCACCACCACGTTTGATTTCCAGCTTGG
LF2 GGAGCCGCCGCCGCCAGAACCACCACCACCAGAACCACCACCACCACGTTTTATTTCCAGCTTGG
LF4 GGAGCCGCCGCCGCCAGAACCACCACCACCAGAACCACCACCACCACGTTTTATTTCCAACTTTG
LF5 GGAGCCGCCGCCGCCAGAACCACCACCACCAGAACCACCACCACCACGTTTCAGCTCCAGCTTGG
Variable heavy chain forward primers
HB1 GGCGGCGGCGGCTCCGGTGGTGGTGA(GT)GT(AG)(AC)AGCTTCAGGAGTC
HB2 GGCGGCGGCGGCTCCGGTGGTGGTGAGGT(GCT)CAGCT(GCT)CAGCAGTC
HB3 GGCGGCGGCGGCTCCGGTGGTGGTCAGGTGCAGCTGAAG(GC)A(GC)TC
HB4 GGCGGCGGCGGCTCCGGTGGTGGTGAGGTCCA(AG)CTGCAACA(AG)TC
HB5 GGCGGCGGCGGCTCCGGTGGTGGTCAGGT(CT)CAGCT(GCT)CAGCA(AG)TC
HB6 GGCGGCGGCGGCTCCGGTGGTGGTCAGGT(CT)CA(AG)CTGCAGCAGTC
HB7 GGCGGCGGCGGCTCCGGTGGTGGTCAGGTCCACGTGAAGCAGTC
HB8 GGCGGCGGCGGCTCCGGTGGTGGTGAGGTGAA(GC)(GC)TGGTGGAATC
HB9 GGCGGCGGCGGCTCCGGTGGTGGTGA(AGC)GTGA(AT)G(CT)TGGTGGAGTC
HB10 GGCGGCGGCGGCTCCGGTGGTGGTGAGGTGCAG(GC)(GT)GGTGGAGTC
HB11 GGCGGCGGCGGCTCCGGTGGTGGTGA(GT)GTGCA(AC)CTGGTGGAGTC
HB12 GGCGGCGGCGGCTCCGGTGGTGGTGAGGTGAAGCTGATGGA(AG)TC
HB13 GGCGGCGGCGGCTCCGGTGGTGGTGAGGTGCA(AG)CTTGTTGAGTC
HB14 GGCGGCGGCGGCTCCGGTGGTGGTGA(AG)GT(AG)AAGCTTCTCGAGTC
HB15 GGCGGCGGCGGCTCCGGTGGTGGTGAAGTGAA(AG)(GC)TTGAGGAGTC
HB16 GGCGGCGGCGGCTCCGGTGGTGGTCAGGTTACTCT(AG)AAAG(AT)GT(GC)TG
HB17 GGCGGCGGCGGCTCCGGTGGTGGTCAGGTCCAACT(AGC)CAGCA(AG)CC
HB18 GGCGGCGGCGGCTCCGGTGGTGGTGATGTGAACTTGGAAGTGTC
HB19 GGCGGCGGCGGCTCCGGTGGTGGTGAGGTGAAGGTCATCGAGTC
Variable heavy chain reverse primers
HF1 ATGCGCGGCCGCCGAGGAAACGGTGACCGTGGT
HF2 ATGCGCGGCCGCCGAGGAGACTGTGAGAGTGGT
HF3 ATGCGCGGCCGCCGCAGAGACAGTGACCAGAGT
HF4 ATGCGCGGCCGCCGAGGAGACGGTGACTGAGGT4 Biotechnology Research International
to 108, incubated in an orbital shaker at 37◦Cf o r1 0m i na n d
plated on 2xYT-AG agar plates. The phage stocks were stored
at 4◦C until use.
2.7. Biopanning of Phage Display Library against PV GP.
Maxisorp Immunotube was (Nunc, Denmark) coated over-
night at 4◦C with PV GP diluted in 50mM of sodium car-
bonate-bicarbonate buﬀer, pH 9.6. After washing the tube
4 times with phosphate-buﬀered saline containing 0.05%
Tween-20 (PBS-T), blocking was done with 1% bovine
gelatin in PBS-T (1% BGPBS-T) and incubated at 37◦Cf o r
2h. The tube was washed as mentioned above and incub-
ated with titrated phages at 37◦C for 2h. Finally the tube
was washed with PBS-T 10 times followed by 10 washes
with PBS. Log phase E. coli TG1 cells were added to the
tubes and incubated at 37◦C to allow infection by bound
phages. Infected culture was twofold serially diluted and
plated on 2xYT-AG agar plates to determine the titer of
phage. The remaining culture was plated and incubated at
37◦C for overnight. The cells were scraped and infected
with helper phage M13K07 and subjected to an additional
rounds of panning. Further panning was done for selection
of high aﬃnity phages with higher stringency using higher
concentrations of Tween-20 that ranged from 0.05% to 0.1%
and also the number of washes from 10 to 20 times.
2.8. Screening Speciﬁc Binding Clones by Phage ELISA. ELISA
was performed to check the binding ability of phage to rabies
virus as described by Clackson et al. [17]. Individual colonies
after third round of biopanning were inoculated into 100μL
of 2xYT containing 100μg/mL ampicillin and 2% glucose
(2xYT-AG) and incubated in an orbital shaker at 37◦Cf o r
overnight. 10μL was subcultured to 100μL/well of 2xYT-
AG media and incubated in an orbital shaker at 37◦Ct i l l
they reached an O.D600 of 0.6. M13K07 helper phage at
a concentration of 2.5 × 1010 pfu/mL was added and the
cultures were further incubated in an orbital shaker for 2h
and then centrifuged at 4000rpm for 20min. The bacterial
pellet was resuspended in 2xYT containing 100μg/mL ampi-
cillin, 50μg/mL kanamycin, and 2% glucose and grown at
30◦C overnight in an orbital shaker. Cells were pelleted,
and the supernatant-containing phages were collected for
analysis in phage ELISA. Brieﬂy, microtiter plates (Nunc,
Roskilde, Denmark) were coated with 100μL/well of 0.05M
carbonate-bicarbonate buﬀer (pH 9.6) containing 5μg/mL
of rabies puriﬁed antigen and incubated overnight at 4◦C.
Blocking was performed using 2% bovine gelatin for 1h at
37◦C using PBS-T followed by incubation with phages at
a concentration of 1011/100μL of bacterial supernatant/well
for 2h at 37◦C. Background noise was estimated using non-
speciﬁc phages in an uncoated microtiter plate. Binding
of the phage particles to antigen was detected with the
horseradish peroxidase-(HRP-)conjugated anti-M13 mouse
antibody(PharmaciaBiotech,dilution1:5000)andfollowed
by 3, 3 ,5 ,5   tetramethylbenzidine (TMB). The plate was
incubated at 37◦C for 10min, and the reaction was stopped
by addition of 1.25M H2SO4. The absorbance was measured
at 450nm using a microplate reader (BIO-TEK, USA).
2.9. Restriction Mapping and Sequence Analysis. The diver-
sity of the selected recombinant clones was checked by
am-plifying the scFv insert using primers light forward
(LB) and heavy chain reverse (HF) followed by digestion
with restriction enzyme BstNI. The banding pattern of
the restriction digestion was analyzed by 3% agarose gel
electrophoresis. Phagemid DNA was isolated using Qiagen
miniprep kit. Each scFv construct was sequenced using S1
and S6 sequencing primers (Amersham Biosciences, USA).
Nucleotide sequence was determined using the standard
protocols from Big Dye Terminator v3.1 cycle sequencing kit
(Applied Biosystems, USA) in conjunction with AB3130XL
automated genetic analyzer (Applied Biosystems, USA). The
sequenceswere analyzedby using IMGT/ V-QUESTsoftware
[18].
2.10. Expression and Puriﬁcation of Soluble Antibody Frag-
ments. Phages, which showed reactivity with rabies virus
were used to isolate plasmid DNA with a commercial kit.
The scFv was ampliﬁed with primers containing EcoRI and
NotIs i t e sa t5   and 3  ends, gel puriﬁed, and cloned into
bacterial expression vector pET 20b and transformed into
E. coli BL21 (DE3) cells. ScFv production was induced
by addition of 1mM isopropyl-β-D-thiogalactopyranoside
(IPTG) and incubated for 4h at 30◦C. The bacterial pellet
was collected by centrifugation at 5000×gf o r2 0m i na t4 ◦C,
resuspended in lysis buﬀer and sonicated. The supernatant
was puriﬁed by immobilized metal aﬃnity chromatography
(IMAC). An IMAC column (5mL) was equilibrated with
10 column volumes of 50mM Tris-HCl, 155mM NaCl, pH
7.6 (equilibration buﬀer). The supernatant was loaded to
the column at a ﬂow rate of 1mL/min and washed with 20
column volumes of washing buﬀer containing equilibration
buﬀerwith30mMimidazole,pH7.6.BoundscFvwaseluted
with 5 column volumes of elution buﬀer containing equili-
brationbuﬀerwith300mMimidazole,pH7.6,asfractionsof
1mL each. Puriﬁed protein was dialysed extensively against
PBS. Protein concentration was deter-mined by the BCA
assay kit (Sigma, USA) and stored at −20◦C till further
use.
2.11. Electrophoresis and Immunoblot Analysis. The puriﬁed
scFv was electrophoresed on a 12% SDS-PAGE [19]. The
separated proteins were transferred to a PVDF membrane
(Hybond-C, Amersham Biosciences, USA) using transblot
apparatus (Bio-Rad, USA) following manufacturer’s instruc-
tions. The blot was probed with His-probe (Pierce, USA)
anddeveloped using 0.05% ofDAB (Sigma,USA) and 0.03%
hydrogen peroxide in PBS.
2.12. Determination of Speciﬁcity of the scFv A11 against
PV GP. The speciﬁcity was determined by (a) immuno-
blot transfer assay, (b) Sandwich ELISA to determine the
reactivity of A11 towards PV GP, (c) Competitive ELISA
to assess the competition of A11 with monoclonal M5B4,
and (d) Binding speciﬁcity of A11 to unrelated viruses. All
the procedures were done as described by Sridevi et al.
[20].Biotechnology Research International 5
2.13. Epitope Mapping of A11 Fragment. The A11 antibody-
bound epitope was mapped with a constrained phage display
peptide library of random peptide 7 mers fused to a minor
coat protein (pIII) of M13 phage. Maxisorp Immunotube
(Nunc, Denmark) was coated overnight at 4◦C with puriﬁed
A11 (50ng/well) diluted in 0.1M NaHCO3 (pH 8.6). The
tubes were washed with PBS-T 5 times and incubated for
2hat4 ◦C with blocking buﬀer, 1% BGPBS-T. The tube was
washed as mentioned above and incubated with 4 × 1010 of
constrained Ph.D.-C7C peptide phage library (New England
Biolabs) at room temperature for 2h. The tube was washed
and bound phages were eluted by disrupting the binding
interactions with 0.2M glycine (pH 2.2), 1mg/mL BSA, and
neutralized with 1M Tris-HCl (pH 9.1). The bound phages
were subjected to three rounds of biopanning as mentioned
above, and the eluted phages from third round were titrated
by infecting E. coli strain ER2738. The clones obtained after
the ﬁnal round of panning/titrations were sequenced, and
analysis of aminoacid sequence of the presented peptide was
deduced to determine the consensus-binding motif.
2.14. Ampliﬁcation of Glycoprotein Gene and Cloning into
pGEX 4T1. To determine the binding site of A11 in PV GP,
the glycoprotein gene was truncated and ampliﬁed as ﬁve
diﬀerent gene products, namely, E1, E2, E3, E4, and E5,
(Table 2(a)) using gene speciﬁc primers and PCR
(Table 2(b)). E1–E5 and pGEX 4T1 were digested using
the restri-ction enzymes BamHI and EcoRI according to the
manufacturer’s instructions (New England Biolabs, MA,
USA) and puriﬁed using a gel puriﬁcation kit. ∼45ng of
each of the digested epitope fragments E1–E5 were ligated
into ∼100ng of digested pGEX 4T1 vector in a total volume
of 20μL using T4 DNA ligase, and the ligated products were
transformed into chemically competent E. coli strain of TOP
10 cells. The plates were incubated overnight at 37◦Ca n d
individual colonies were picked from each plate, inoculated
into the medium containing ampicillin, and grown at 37◦C
in an orbital shaker for overnight. The overnight grown
culture was used for isolation of plasmids using plasmid
mini-prep kit from QIAGEN, and positive clones were
conﬁrmed by restriction double digestion and sequence
analysis.
2.15. Expression and Puriﬁcation of Glycoprotein Epitope
Genes. pGEX 4T1 E1–E5 plasmids were transformed into
BL21 (DE3) cells of E. coli strain. Individual colonies were
picked, and each of the culture expressing epitopes E1–E5
regions of glycoprotein was induced by addition of 1mM
IPTG and incubated for 4h at 30◦C. The bacterial pellet was
collected by centrifugation at 5000×gf o r2 0m i na t4 ◦Ca n d
resuspended in lysis buﬀer and sonicated. The supernatant
was puriﬁed by glutathione agarose column. Puriﬁed protein
was dialysed extensively against PBS. Protein concentration
was determined by the BCA assay kit (Sigma, USA) and
stored at −20◦C for further characterization.
2.16. Indirect ELISA for Epitope Speciﬁcity. A microtiter plate
(Nunc, Denmark) was coated with 100ng/well of E1–E5 in
12 M 34
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Figure 1: Agarose gel electrophoresis analysis of PCR-ampliﬁed
products from immunized splenocytes. Lane M shows the DNA
ladder and Lanes 1, 2, and 3 show the variable heavy, variable light
chain genes, and assembled PCR products, respectively. Lane 4 is
the recombinant expression cassette after NcoIa n dNotI digestion
showing release of scFv product.
50mM carbonate-bicarbonate buﬀer (pH 9.6), respectively,
and incubated overnight at 4◦C. The plate was washed thrice
with PBS-T and blocked with 1% BGPBS-T followed by
washing with PBS-T. 20ng/100μL of A11 was added in the
ﬁrst well, serial diluted, and incubated at 37◦Cf o r1h .T h e
plate was washed ﬁve times with PBS-T and dried. The bind-
ing of the A11 with diﬀerent epitopes of PV GP was detected
by addition of His-probe and a chromogenic substrate TMB.
The reaction was stopped by addition of 1.25M H2SO4,a n d
the absorbance was measured at 450nm using a microplate
reader (BIO-TEK, USA). The experiment was done in
triplicates to evaluate the concentration-dependent binding
activity of A11 towards diﬀerent epitopes of PV GP.
3. Results
3.1. Ampliﬁcation and Cloning of VH and VL Genes to Form
scFv Phage Display Cassette. Total RNA was isolated from
immunizedmicespleencellsandcDNAwassynthesized.The
cDNA was used as a template for the PCR ampliﬁcation of
the VH and VL genes by using universal primers (Table 1),
which yielded a 321bp and 303bp amplicon as shown in
Figure 1, Lanes 1 and 2, respectively. The resultant VH and
VL were assembled into a single chain fragment using a
peptide linker (Gly4Ser)3 using SOE PCR which could be
visualized as a 750bp amplicon on the agarose gel as shown
in Figure 1, Lane 3. The scFv was digested by NcoI/NotI
and ligated into the phage display vector pCANTAB 5E to
form the cassette yielding a library of 4.2 × 107 pfu/mL. The6 Biotechnology Research International
Table 2: (a) Location of selected epitopes present on PV GP and its size in base pairs (bp). (b) Primers used for ampliﬁcation of epitope
coding regions of PV GP and cloning into pGEX vector.
(a)
Epitope gene ID Location on PV GP Size in bp
E1 3318–3640 322
E2 3641–3888 247
E3 3889–4134 238
E4 4135–4380 245
E5 4381–4697 316
(b)
Epitope 1 For ATCGGGATCCGGAGTATTTTTCAATGGTATAAT
Epitope 1 Rev ATCGGAATTCTCCTCTGAGATTGTGTTGT
Epitope 2 For ATCGGGATCCGGAGTATTTTTCAATGGTATAAT
Epitope 2 Rev ATCGGAATTCCCGTTCGTGCACATCG
Epitope 3 For ATCGGGATCCAAGAACGGTGACGAGG
Epitope 3 Rev ATCGGAATTCCCGTTCGTGCACATCG
Epitope 4 For ATCGGGATCCCAGCAACATATGGAGTTGT
Epitope 4 Rev ATCGGAATTCCAAGGCAGTCAGGGCC
Epitope 5 For ATCGGGATCCTGCCCAAACAATTTGGTA
Epitope 5 Rev ATCGGAATTCCCCGTTCATTTTTATGGC
presence of scFv in the library was analyzed by NcoI/NotI
digestion as shown in Figure 1,L a n e4 .
3.2. Selection of Phage Displaying Antirabies Recombinant
Antibodies by Biopanning. An scFv phage display library
containing 1 × 1012 pfu/mL of independent clones was sub-
jected to biopanning for selection of scFvs against PV GP.
Enrichment of antigen-speciﬁc binding phage was measured
byperformingthethreeroundsofpanning,whichresultedin
1×103,1×105,and1×109 pfuofelutedphageinﬁrst,second
and third rounds of panning, respectively. Antigen-binding
activityofthepooledphagesfromeachroundofthepanning
was analyzed by phage ELISA, resulting in the successful
en-richment of rabies-virus-speciﬁc binders as shown in
Figure 2. Eluted phages from round 3 were used to infect E.
coli TG1 to produce phage antibodies, and the supernatants
containing phage antibodies from 96 individual clones were
tested by phage ELISA against PV GP, to select antigen-
speciﬁc phage scFvs. Of the 96 clones tested, 30 showed posi-
tive binding to rabies virus. PCR analysis conﬁrmed that the
selected clones contained an insert corresponding to the size
of an scFv fragment. DNA sequence analysis of two strongest
binding clones, A11 and D11, showed similar VH and VL
sequences. All further studies were done using A11.
3.3. DNA Fingerprint Analysis Using Restriction Fragment
Length Polymorphism (RFLP). To determine the diversity
of the library, PCR-ampliﬁed scFv fragments from 30
individual clones of scFv library were analyzed by BstNI
ﬁngerprinting. Each scFv showed a diﬀerent digestion pat-
tern indicating variations in BstNI recognition sites con-
ﬁrming diversity amongst randomly selected clones. To
conﬁrm that the scFvs consisted of VH and VL chains of
immunoglobulin molecules and to further analyze library
diversity, DNA sequence analysis was performed on 30 ran-
domly selected clones obtained from an scFv library. All
scFv sequences were analyzed using the web-based NCBI
Ig BLAST program (http://www.ncbi.nlm.nih.gov/igblast/)
and IMGT/V-QUEST software to approximate framework
and complementarity determining regions. In the library
sequenced,themajorityofVHandVLchainshadopenread-
ing frames encoding full-length VH and VL chains (data not
shown).
3.4.ExpressionandPuriﬁcationofSolublescFvA11. Sequence
analysis of scFv A11 by International ImmunoGeneTics
information system (IMGT) revealed the presence of 223
amino acids as shown in Figure 3. ScFv A11 was transformed
into E. coli BL21 (DE3) for production of soluble scFv for
further characterization. The puriﬁed protein eluted fraction
of scFv shows a ∼28kDa band on both SDS-PAGE and im-
munoblot analysis as indicated in Figure 4.
3.5. Reactivity of A11 with Rabies Virus Glycoprotein. Im-
munoblotting of A11 and M5B4 against the rabies virus
structural proteins resolved in a 10% gel by nonreducing
SDS-PAGE clearly indicated binding to a ∼66kDa protein
corresponding to PV GP as indicated in Figure 5. The PV-
NP-speciﬁc MAb-N5G4 was used as a negative control and
it bound to a ∼55kDa protein corresponding to rabies virus
nucleoprotein (PV NP).
3.6. Sandwich ELISA. Sandwich ELISA was performed to
determine the reactivity of the A11. Titration of the PV GPBiotechnology Research International 7
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Figure 2: Phage ELISA showing the enrichment of phages speciﬁc
for rabies virus glycoprotein during the panning cycles. After each
round of panning, the output phages were added to microtiter wells
with200ngofPVGPorbovinegelatin.Anti-M13andhelperphage
was used as a control to check the back ground value. Bound phages
were detected by horseradish peroxidase (HRP) conjugated anti-
M13 antibody.
GYQMTQTTSSLSASLRDRVTISCRASQDITNYLNWYQQKPDGTVK
LLIYYASNLHSGVPSRFSGSGSGTDYSLTISNLEPEDIATYYCQCSKVP
YTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLQQSGAELVRPKDYY
MHWVKQRPEQGLEWIGRIDPENGNTKYDPKFQGKATITADTSSNTA
YSLQLSSLTSEDTAVYYCARGGAMDYWGQGTSVTVSS
EF
AAA
Figure 3: Amino acid sequence of anti-rabies mouse scFv contain-
ing VL, linker peptide and VH. The linker peptide is marked in
italics. The restriction enzyme sites for cloning of the scFv gene are
underlined.
against a constant dilution of A11 revealed a concentration-
dependent reduction of the binding signal as shown in
Figure 6. The control showed no reactivity in ELISA indicat-
ing the speciﬁcity of the A11.
3.7. Competitive ELISA to Determine Site Speciﬁcity of A11.
Competitive ELISA was performed to determine the com-
petition between M5B4 [21] and the A11 for the same site
on PV GP. No competition as detected when the constant
amount of M5B4 was allowed to compete with varying
twofold dilutions of A11. There was no change in the optical
density following the dilution of the A11 indicating that it
did not compete for the same site on PV GP as shown in
Figure 7. Antirabies diabody was used as a positive control
[20].
M 1 23
175kDa
83kDa
62kDa
47.5kDa
32.5kDa
25kDa
16.5kDa
Figure 4: Detection of recombinant A11 on 12% sodium dodecyl
sulphate-polyacrylamide gel electrophoresis. Lane M shows protein
molecular size standard. Lane 1 is a puriﬁed protein transferred
o n t oP V D Fm e m b r a n ea n dp r o b e dw i t hH i s - p r o b ea n dd e v e l o p e d
using DAB substrate. Lanes 2 and 3 are a puriﬁed protein and crude
lysate stained with coomassie brilliant blue R-250.
3.8. Cross Reactivity of A11 to Unrelated Proteins. Antigen
speciﬁcity of the A11 was veriﬁed by reactivity in ELISA
againsthepatitisA,hepatitisB,andchikungunyaviruses.The
comparison of the absorbance values, as shown in Figure 8,
indicated that A11 reacted only with rabies virus in a
concentration-dependent manner and showed no reactivity
towards other viruses.
3.9. Epitope Mapping. A constrained heptapeptide library
displayed on ﬁlamentous phage was screened on coated
scFv A11. Following four rounds of panning/selection,
10 clones were selected of which 7 bound to the same
constrained heptapeptide (SGPSYTT). A sequence similarity
between the constrained peptide recognized by A11 and the
conformational antigen site II of PV GP at nucleic acid
sequence 3489–3503 (SGFSY) strongly suggested that A11
bound to the antigenic site II of PV GP.
3.10. Ampliﬁcation of Various Regions of the Glycoprotein
Gene and Cloning into pGEX 4T1. P VG Pw a su s e da sa
template for the PCR ampliﬁcation (94◦C for 1min, 50◦C
1min, 72◦C 1min, for 34 cycles) of the epitope regions (E1,
E2, E3, E4 and E5) (Table 2(a)) by respective gene-speciﬁc
primers (Table 2(b)) yielded 322bp, 247bp, 238bp, 245bp,
and 316bp amplicons, respectively (data not shown). The
resultant epitope regions were digested with BamHI and
EcoRI and ligated into the bacterial expression vector pGEX
4T1 to yield pGEX 4T1 E1–E5.
3.11. Expression and Puriﬁcation of Glycoprotein Epitope
Regions. pGEX 4T1 E1–E5 containing glycoprotein epitopes
(E1–E5) was transformed into BL21 (DE3) cells and was
expressed by induction with 1mM IPTG. The cell pellet was8 Biotechnology Research International
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Figure5:ReactivityoftheA11withtherabiesvirusglycoproteininimmuno-transferblotanalysis.LaneN5G4wasdevelopedusingantibody
speciﬁc to nucleoprotein of rabies virus. Lane M5B4 was developed using antibody speciﬁc to glycoprotein site III of rabies virus. Lane A11
was developed using A11 speciﬁc to glycoprotein of rabies virus. Lane M shows protein molecular size standard.
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Figure 6: Analysis of antigen binding aﬃnity of A11 by ELISA to
evaluate the activity of A11 to rabies virus glycoprotein. Negative
control used for ELISA is E. coli lysate, and positive control is anti-
rabies diabody.
lysed, and the cytoplasmic fraction was puriﬁed on a gluta-
thione agarose column. Analysis of the puriﬁed GST fusions
E1–E5 by coomassie staining and immunoblotting (data not
shown) indicated the presence of a 38, 35, 35, 35, and 37kDa
bands, respectively. The yield of glycoprotein epitope regions
E1–E5 ranged from 1.8 to 2.0mg/liter of culture.
3.12. Indirect ELISA for Epitope Speciﬁcity. Indirect ELISA
was performed to determine the speciﬁcity of A11 towards
E1–E5. Titration of the A11 against a constant dilution of
diﬀerent polypeptides of PV GP revealed a concentration-
dependent reduction of the binding signal in the wells coated
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Figure 7: Competitive ELISA using the A11 and the RV GP-speciﬁc
human antirabies diabody and mouse Mab M5B4 speciﬁc for site
III.
only with E1 as shown in Figure 9, indicating that A11 binds
strongly with E1 epitope, which codes for the aminoacid
sequence SGFSY present in the antigenic site II of PV GP.
4. Discussion
Antibody engineering using phage display technology [22]
allowed the expression of scFvs on the surface of bac-
teriophage [12] thereby oﬀering several advantages over
hybridoma technology which included generation of anti-
bodies with increased aﬃnity and speciﬁcity by mimicking
aﬃnitymaturationinnormalimmunesystem.ThisprovidedBiotechnology Research International 9
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Figure 8: ELISA-based comparison of A11 (at diﬀerent concentra-
tions) binding to unrelated viruses showing that the antibody binds
to rabies virus and does not show any reactivity to Hepatitis A virus
(HAV), Hepatitis B surface antigen (HB), and Chikungunya virus
(CHIKV). The data shown are the representative of three similar
experiments and are the mean of triplicate samples.
an antibody with a stable genetic source, which could be eas-
ily manipulated allowing their usage in various clinical dia-
gnosis and therapeutic applications [23–28]. An enormous
number of antibody fragments (upto 109 clones) could be
isolated from a single immunized animal, and the aﬃnity of
these antibodies could be increased by in vitro aﬃnity mat-
uration [29, 30].
Inthisstudy,weconstructedanscFvlibraryfrommurine
splenocytes, which was directed against the PV GP using
phage display technology. scFvs were expressed on the phage
as membrane-anchored proteins, which allowed us to per-
form antibody selection very eﬃciently and further allowed
the isolation of the best candidate through biopanning.
Following three rounds of biopanning, 30 PV GP positive
phage clones were selected by phage ELISA of which only 2
cloneselicitedaverystrongsignalinELISA.DNAsequencing
of these clones identiﬁed them as variable antibody genes be-
longingtotheIgG1subgroupandshowed100%similarity in
their sequences. One was selected for further studies.
The scFvs are expressed on the phage surface fused to the
minor coat protein III, separated by an amber codon in TG1
strain of Escherichia coli, which facilitated numerous cycles
of selection and infection. To achieve optimum expression of
A11 as a soluble product, phagemid isolated from positive
clones were ampliﬁed with primers containing restriction
sites, and the resultant PCR product was cloned into a
bacterial expression vector pET 20b. Expression in E. coli
resulted in the expression of a soluble ∼28kDa protein A11,
which was puriﬁed to ∼90% homogeneity using IMAC.
Puriﬁcation of the bacterial lysate resulted in the yield
∼4mg of puriﬁed A11/liter of culture with a homogeneity
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Figure 9: Analysis of epitope-binding aﬃnity of A11 by ELISA to
evaluate the activity of A11 to rabies virus glycoprotein epitopes.
The data shown are the representative of three similar experiments
and are the mean of triplicate samples.
of ∼90–95%. The ease of puriﬁcation reiterated the fact
that expression of a functional recombinant antibody in
bacteria oﬀered many advantages over the maintenance of a
hybridoma cell line, which included minimal batch-to-batch
variation, ease of scale up, and so forth, at a reasonable cost.
The binding of A11 to PV GP in ELISA indicated proper
folding of the protein following expression. A11 binding to
PVGPwasdemonstratedbywesternblotanalysis.Speciﬁcity
study showed that the A11 reacted only with PV GP but not
with other viruses as indicated by sandwich ELISA. A11 did
not compete with M5B4 for binding to PV GP, suggesting
that A11 and M5B4 bound to diﬀerent epitopes.
A large number of other researchers have mapped the
various antigenic sites using mutational analysis on the
glycoprotein of MAb-resistant variants [31–35], and they
includeantigenicsiteIlocatedataa231[36],antigenicsiteII,
which is a discontinuous conformational epitope comprising
aa 34 to 42 and aa 198 to 200 antigenic site III which is a
continuous conformational epitope at aa 330 to 338 and is
involved in viral pathogenicity [37, 38], and antigenic site
IV is known to harbor overlapping linear epitopes [39–41].
The binding site of A11 was mapped using a constrained
phage display library to facilitate the chance of selecting
conformational peptides, which were complementary to
the A11 paratope. The disulﬁde-constrained heptapeptides
were expressed at the N-terminus of the pIII protein of
the ﬁlamentous phage with the ﬁrst cysteine preceded by
an alanine residue, the second cysteine followed by short
spacer (Gly-Gly-Gly-Ser), and the wildtype pIII sequence in
tandem [42–44]. A11 bound to the C-SGPSYTT-C which
showed sequence similarity with the PV GP site II (SGFSY)10 Biotechnology Research International
corresponding to the nucleic acid position 3489–3503 of the
PV GP gene. Further, the binding of A11 on native PV GP
was determined by expressing truncated fragments based on
the known gene sequences of PV GP. Fragments of antigen
gene were ampliﬁed and cloned into pGEX 4T1 bacterial
expression vector and expressed as a GST fusions E1–E5.
The fragments of the antigen were expressed and puriﬁed
byaﬃnitychromatographyusingglutathione-agarose,which
permits rapid, mild, nondenaturing, and highly selective
puriﬁcation of binding enzymes such as GST. An ELISA
study of these puriﬁed fragments clearly indicated that the
selected A11 bound to E1, which encompassed the site II of
PV GP and included the site SGFSY.
In conclusion, a mouse immune scFv library was con-
structed from splenocytes of PV immunized mice. The
constructed mouse scFv library revealed and conﬁrmed the
broad diversity by BstNI ﬁngerprinting and DNA sequence
analysis. The selected scFv fragment A11 was shown to bind
to site II of PV GP both by the use of a constrained library
and a truncated PV GP encompassing the site II. The data
presented not only deﬁned the functional aspects of the
scFv but also reiterated the fact that this methodology could
be used as a means for quick development of recombinant
antibodies against rabies and other infectious diseases. The
antibodies thus developed could be used not only for
postexposure prophylaxis of rabies but would also allow us
to address the issue of natural variation amongst rabies virus
ﬁeld isolates.
Abbreviations
cDNA: Complementary DNA
DAB: 3, 3  diaminobenzidine
DNA: Deoxyribonucleic acid
GP: Glycoprotein
OD: Optical density
RNA: Ribonucleic acid
RT-PCR: Reverse transcription-polymerase chain
reaction
scFv: single-chain Fv antibody fragment
VH: Variable heavy chain
VL: Variable light chain.
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